Ovid Therapeutics Inc Quick Ratio (OVID) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Ovid Therapeutics Inc   (NASDAQ: OVID)

Ovid Therapeutics Inc 's Quick Ratio

OVID's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.16 below Ovid Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Quick Ratio than Ovid Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 206 to 279.

Explain Quick Ratio?
How much Cash & cash equivalents OVID´s has?
What are OVID´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/OVID/financial-strength
https://api.csimarket.com/api/v1/companies/OVID/fundamentals
https://api.csimarket.com/api/v1/companies/OVID/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
OVID Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 74.48 %
Y / Y Cash & cash equivalent Change -46.06 %
Quick Ratio MRQ 1.16
OVID's Total Ranking # 279
Seq. Current Liabilities Change 18.82 %
Seq. Cash & cash equivalent Change -91.86 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 53
Healthcare Sector # 81
Overall Market # 279


Quick Ratio Statistics
High Average Low
20.94 10.65 2.84
(Sep 30 2017)   (Jun 30 2020)




Financial Statements
Ovid Therapeutics Inc 's Current Liabilities $ 12 Millions Visit OVID's Balance sheet
Ovid Therapeutics Inc 's Cash & cash equivalent $ 14 Millions Visit OVID's Balance sheet
Source of OVID's Sales Visit OVID's Sales by Geography


Cumulative Ovid Therapeutics Inc 's Quick Ratio

OVID's Quick Ratio for the trailling 12 Months

OVID Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 25.72 %
Y / Y Cash & cash equivalent TTM Growth 155.43 %
Quick Ratio TTM 9.51
Total Ranking TTM # 401
Seq. Current Liabilities TTM Growth 13.35 %
Seq. Cash & cash equivalent TTM Growth -2.8 %

Quick ratio ranking by company, industry and sector >> Back to OVID Financial Strength Comparisons >> Go to Compare OVID Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $11.86 millions, cumulative Quick Ratio decreased to 9.51 above the OVID average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 417 other companies have achieved higher Quick Ratio than Ovid Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3418, from total ranking during the twelve months ending second quarter 2026 at 3512.

Explain Quick Ratio?
How much Cash & cash equivalents OVID´s has?
What are OVID´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 418
Healthcare Sector # 852
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
15.91 6.12 2.02
(Dec 31 2021)   (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Cytokinetics Incorporated  3.20 $ 1,130.021  Millions$ 353.419  Millions
Elicio Therapeutics Inc   3.11 $ 30.900  Millions$ 9.930  Millions
Talphera Inc   3.06 $ 14.157  Millions$ 4.630  Millions
Harmony Biosciences Holdings inc   3.02 $ 771.138  Millions$ 254.981  Millions
Phio Pharmaceuticals Corp  2.96 $ 10.609  Millions$ 3.583  Millions
Zevra Therapeutics Inc   2.95 $ 122.148  Millions$ 41.369  Millions
Nextcure Inc   2.95 $ 8.728  Millions$ 2.960  Millions
Pyxis Oncology Inc   2.79 $ 55.572  Millions$ 19.942  Millions
Zenas Biopharma Inc   2.78 $ 177.778  Millions$ 64.043  Millions
Ptc Therapeutics inc   2.74 $ 2,127.918  Millions$ 776.076  Millions
Annexon Inc   2.72 $ 102.389  Millions$ 37.660  Millions
Turn Therapeutics Inc   2.71 $ 9.433  Millions$ 3.479  Millions
Beone Medicines Ltd   2.67 $ 5,955.905  Millions$ 2,233.923  Millions
Biohaven Ltd   2.57 $ 161.125  Millions$ 62.767  Millions
Altimmune inc   2.51 $ 28.888  Millions$ 11.526  Millions
Ironwood Pharmaceuticals inc   2.49 $ 86.376  Millions$ 34.733  Millions
Azitra Inc   2.44 $ 3.751  Millions$ 1.540  Millions
Tg Therapeutics Inc   2.43 $ 632.004  Millions$ 260.526  Millions
Adc Therapeutics Sa  2.42 $ 189.204  Millions$ 78.125  Millions
Dermata Therapeutics Inc   2.40 $ 4.822  Millions$ 2.012  Millions
Opko Health Inc   2.37 $ 384.036  Millions$ 162.356  Millions
Pacira Biosciences inc   2.31 $ 295.577  Millions$ 128.209  Millions
Dogwood Therapeutics inc   2.28 $ 4.948  Millions$ 2.174  Millions
Ardelyx inc   2.23 $ 285.338  Millions$ 127.805  Millions
Schrodinger Inc   2.20 $ 366.358  Millions$ 166.292  Millions
Stoke Therapeutics Inc   2.19 $ 107.271  Millions$ 48.977  Millions
Quantum Cyber N v   2.17 $ 5.032  Millions$ 2.319  Millions
Maravai Lifesciences Holdings Inc   2.14 $ 73.023  Millions$ 34.160  Millions
Ernexa Therapeutics Inc   2.13 $ 5.575  Millions$ 2.614  Millions
Madrigal Pharmaceuticals Inc   2.12 $ 962.387  Millions$ 454.244  Millions

Date modified: 2026-11-11T13:54:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.